Mepolizumab is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction in allergic symptoms of asthma and hypereosinophilic syndromes. Mepolizumab has not been associated with serum enzyme elevations during therapy or to instances of clinically apparent drug induced liver injury. It is grouped under the following drug class(es): Interleukin Inhibitors. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Nucala, Bosatria and mepolizumabum. Its PubChem SID is 481101752.
Mepolizumab
| CAS No | 196078-29-2 |
|---|---|
| Molecular Formula | N/A |
| Molecular Weight | ~149,000 g/mol |
| Synonyms | N/A |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Mepolizumab is a humanized monoclonal antibody to interleukin-5 (IL-5) which leads to a decrease in production and maturation of eosinophils and results in a reduction in allergic symptoms of asthma and hypereosinophilic syndromes.
The listed CAS number is 196078-29-2.
The listed molecular formula is N/A.
The listed molecular weight is ~149,000 g/mol.
N/A.
The source lists Nucala, Bosatria and mepolizumabum.